Sentences with phrase «others at an increased risk»

Others at increased risk include women who have had breast, uterine or colon cancer and women who have never been pregnant.

The standard of care requires that drivers do not put others at an increased risk of harm.

This means having a valid driver's license, obeying the rules of the road, and operating the vehicle in a manner that does not put others at an increased risk of harm.

Violations of this duty put others at an increased risk of harm.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Many factors could cause BlackBerry's actual results, performance or achievements to differ materially from those expressed or implied by the forward - looking statements, including, without limitation: BlackBerry's ability to enhance its current products and services, or develop new products and services in a timely manner or at competitive prices, including risks related to new product introductions; risks related to BlackBerry's ability to mitigate the impact of the anticipated decline in BlackBerry's infrastructure access fees on its consolidated revenue by developing an integrated services and software offering; intense competition, rapid change and significant strategic alliances within BlackBerry's industry; BlackBerry's reliance on carrier partners and distributors; risks associated with BlackBerry's foreign operations, including risks related to recent political and economic developments in Venezuela and the impact of foreign currency restrictions; risks relating to network disruptions and other business interruptions, including costs, potential liabilities, lost revenues and reputational damage associated with service interruptions; risks related to BlackBerry's ability to implement and to realize the anticipated benefits of its CORE program; BlackBerry's ability to maintain or increase its cash balance; security risks; BlackBerry's ability to attract and retain key personnel; risks related to intellectual property rights; BlackBerry's ability to expand and manage BlackBerry (R) World (TM); risks related to the collection, storage, transmission, use and disclosure of confidential and personal information;

Many factors could cause BlackBerry's actual results, performance or achievements to differ materially from those expressed or implied by the forward - looking statements, including, without limitation: BlackBerry's ability to enhance its current products and services, or develop new products and services in a timely manner or at competitive prices, including risks related to new product introductions; risks related to BlackBerry's ability to mitigate the impact of the anticipated decline in BlackBerry's infrastructure access fees on its consolidated revenue by developing an integrated services and software offering; intense competition, rapid change and significant strategic alliances within BlackBerry's industry; BlackBerry's reliance on carrier partners and distributors; risks associated with BlackBerry's foreign operations, including risks related to recent political and economic developments in Venezuela and the impact of foreign currency restrictions; risks relating to network disruptions and other business interruptions, including costs, potential liabilities, lost revenues and reputational damage associated with service interruptions; risks related to BlackBerry's ability to implement and to realize the anticipated benefits of its CORE program; BlackBerry's ability to maintain or increase its cash balance; security risks; BlackBerry's ability to attract and retain key personnel; risks related to intellectual property rights; BlackBerry's ability to expand and manage BlackBerry ® World ™; risks related to the collection, storage, transmission, use and disclosure of confidential and personal information; BlackBerry's ability to manage inventory and asset risk; BlackBerry's reliance on suppliers of functional components for its products and risks relating to its supply chain; BlackBerry's ability to obtain rights to use software or components supplied by third parties; BlackBerry's ability to successfully maintain and enhance its brand; risks related to government regulations, including regulations relating to encryption technology; BlackBerry's ability to continue to adapt to recent board and management changes and headcount reductions; reliance on strategic alliances with third - party network infrastructure developers, software platform vendors and service platform vendors; BlackBerry's reliance on third - party manufacturers; potential defects and vulnerabilities in BlackBerry's products; risks related to litigation, including litigation claims arising from BlackBerry's practice of providing forward - looking guidance; potential charges relating to the impairment of intangible assets recorded on BlackBerry's balance sheet; risks as a result of actions of activist shareholders; government regulation of wireless spectrum and radio frequencies; risks related to economic and geopolitical conditions; risks associated with acquisitions; foreign exchange risks; and difficulties in forecasting BlackBerry's financial results given the rapid technological changes, evolving industry standards, intense competition and short product life cycles that characterize the wireless communications industry.

Effective January 1, 2011, upon the recommendation of the GNC, the Board increased to $ 25,000 the annual fee paid to the chair of each standing Board committee other than the AEC, which remained at $ 30,000; set at $ 25,000 the annual fee paid to the chairs of the CRC and Risk Committee, which were formed effective January 1, 2011; eliminated the annual stock option grant; and increased the value of the annual stock award to $ 140,000.

This is evident in a number of developments, including: increased demand for higher - risk assets; the increase in «carry trades» — a form of gearing where funds are borrowed short - term at low interest rates and invested in higher - yielding assets, often in other countries; growth in alternative investment vehicles such as hedge funds; and growth in alternative investment strategies such as selling embedded options (see Box A).

Examples of these risks, uncertainties and other factors include, but are not limited to the impact of: adverse general economic and related factors, such as fluctuating or increasing levels of unemployment, underemployment and the volatility of fuel prices, declines in the securities and real estate markets, and perceptions of these conditions that decrease the level of disposable income of consumers or consumer confidence; adverse events impacting the security of travel, such as terrorist acts, armed conflict and threats thereof, acts of piracy, and other international events; the risks and increased costs associated with operating internationally; our expansion into and investments in new markets; breaches in data security or other disturbances to our information technology and other networks; the spread of epidemics and viral outbreaks; adverse incidents involving cruise ships; changes in fuel prices and / or other cruise operating costs; any impairment of our tradenames or goodwill; our hedging strategies; our inability to obtain adequate insurance coverage; our substantial indebtedness, including the ability to raise additional capital to fund our operations, and to generate the necessary amount of cash to service our existing debt; restrictions in the agreements governing our indebtedness that limit our flexibility in operating our business; the significant portion of our assets pledged as collateral under our existing debt agreements and the ability of our creditors to accelerate the repayment of our indebtedness; volatility and disruptions in the global credit and financial markets, which may adversely affect our ability to borrow and could increase our counterparty credit risks, including those under our credit facilities, derivatives, contingent obligations, insurance contracts and new ship progress payment guarantees; fluctuations in foreign currency exchange rates; overcapacity in key markets or globally; our inability to recruit or retain qualified personnel or the loss of key personnel; future changes relating to how external distribution channels sell and market our cruises; our reliance on third parties to provide hotel management services to certain ships and certain other services; delays in our shipbuilding program and ship repairs, maintenance and refurbishments; future increases in the price of, or major changes or reduction in, commercial airline services; seasonal variations in passenger fare rates and occupancy levels at different times of the year; our ability to keep pace with developments in technology; amendments to our collective bargaining agreements for crew members and other employee relation issues; the continued availability of attractive port destinations; pending or threatened litigation, investigations and enforcement actions; changes involving the tax and environmental regulatory regimes in which we operate; and other factors set forth under «Risk Factors» in our most recently filed Annual Report on Form 10 - K and subsequent filings by the Company with the Securities and Exchange Commission.

«As consumer awareness continues to increase, more and more restaurants and other foodservice operations are discovering gluten - free products as a mechanism to build loyalty by catering to special dietary needs,» says Tina Battistoni, a senior marketing manager at Rich Products Corp. «Rich's gluten - free products are certified by the Gluten - Free Certification Organization [GFCO],» she explains, «and are individually wrapped to mitigate risk of cross-contamination.

One way, I believe, to address the problem of under - reporting and increase the chances a concussion will be identified early on the sports sideline may be to rely less on athletes themselves to remove themselves from games or practices by reporting concussion symptoms (which the most recent study shows occurs at a shockingly low rate, [9] or on game officials and sideline observers to observe signs of concussion and call for a concussion assessment, but to employ technology to increase the chances that a concussion will be identified by employing impact sensors designed to monitor head impact exposure in terms of the force of hits (both linear and rotational), number, location, and cumulative impact, in real time at all levels of football, and in other helmeted and non-helmeted contact and collision sports, where practical, to help identify high - risk impacts and alert medical personnel on the sideline so they can consider performing a concussion assessment.

If you have symptoms of depression during or after a previous pregnancy, a history of depression or other mood disorders at another time in your life, or a family member who has been diagnosed with depression or other mental illness, your risk of PPD is increased.

In other words, any way you choose to look at it, no matter how carefully you slice and dice the data, there is simply no getting around the fact that homebirth increases the risk of perinatal death and brain damage.

They partner with other organizations to increase access to quality early childhood education for low - income children, address the impact of childhood traumas and enhance parental engagement with at - risk children's social and emotional learning.

The Newborn Hearing Feasibility Study will explore whether the routine newborn hearing test, either alone or in combination with other risk factors, can be used immediately after birth to identify babies at increased risk of unexpected death later in infancy.

The baby will be at a higher risk for having a depressed immune system, an increased risk of respiratory problems, low blood sugar, temperature regulation problems and many other possible complications.

These include the infant with galactosemia, 53,54 the infant whose mother uses illegal drugs, 55 the infant whose mother has untreated active tuberculosis, and the infant in the United States whose mother has been infected with the human immunodeficiency virus.56, 57 In countries with populations at increased risk for other infectious diseases and nutritional deficiencies resulting in infant death, the mortality risks associated with not breastfeeding may outweigh the possible risks of acquiring human immunodeficiency virus infection.58 Although most prescribed and over-the-counter medications are safe for the breastfed infant, there are a few medications that mothers may need to take that may make it necessary to interrupt breastfeeding temporarily.

The risk of death due to diarrhea and other infections increases when babies are either partially breastfed or not breastfed at all.

Bottle - fed babies «are at increased risk for baby bottle caries, a destructive dental condition which occurs when a baby is put to bed with a bottle containing formula, milk, juice or other fluids high in carbohydrates.

Other risk factors to increase the risk of third and fourth degree tearing at second birth include; high birth weight, forceps delivery and the presence of shoulder dystocia.

Babies are at increased risk of death if they co-sleep with more persons than their parents (eg other siblings) 29 or with a pet.30 Co-sleeping with a sibling raises the risk.31 Babies should not co-sleep if anyone other than the parents is in the bed.

There is no denying the evidence that labour inductions increase the risk of a cascade of other non-natural interferences which put both the mother and baby at risk.

«Elective deliveries prior to 39 weeks definitely have some increased morbidity,» says Abdulla Al - Khan, MD, the director and chief of maternal and fetal medicine and surgery at Hackensack University Medical Center in New Jersey Other factors such as type of delivery and reason for early term delivery also affect these risks, he says.

Cobedding of twins and other infants of multiple gestation is a frequent practice, both in the hospital setting and at home.174 However, the benefits of cobedding twins and higher - order multiples have not been established.175, — , 177 Twins and higher - order multiples are often born prematurely and with low birth weight, so they are at increased risk of SIDS.101, 102 Furthermore, there is increased potential for overheating and rebreathing while cobedding, and size discordance might increase the risk of accidental suffocation.176 Most cobedded twins are placed on their sides rather than supine.174 Finally, cobedding of twins and higher - order multiples in the hospital setting might encourage parents to continue this practice at home.176 Because the evidence for the benefits of cobedding twins and higher - order multiples is not compelling and because of the increased risk of SIDS and suffocation, the AAP believes that it is prudent to provide separate sleep areas for these infants to decrease the risk of SIDS and accidental suffocation.

Preterm infants are at increased risk of SIDS, 12,13 and the association between prone sleep position and SIDS among low birth weight infants is equal to, or perhaps even stronger than, the association among those born at term.14 Preterm infants and other infants in the NICU should be placed in the supine position for sleep as soon as the infant is medically stable and significantly before the infant's anticipated discharge, by 32 weeks» postmenstrual age.15 NICU personnel should endorse safe - sleeping guidelines with parents of infants from the time of admission to the NICU.

«These findings are quite exciting and further research should be done to confirm them, especially in women at increased risk of postpartum depression and in women from other cultures,» Wisner said.

Other investigators have reported a significant increase in adverse perinatal outcomes related to planned home births, especially where skilled birth attendants are not universally integrated into regional health systems, or in population - based studies that include at - risk pregnancies [20 — 22].

There are currently more than 6.6 million households across the UK who can not afford to heat their homes, putting them at risk of serious health problems such as heart disease, strokes, respiratory illnesses - such as asthma and bronchitis - and exacerbating common ailments like colds and flu as well as increasing the likelihood of falls and other accidents.

When children are not vaccinated, they are at increased risk for diseases and can also spread these diseases to others in their classrooms and community — including babies who are too young to be fully vaccinated, and people with weakened immune systems due to cancer or other health conditions.

According to officials at the state Department of Corrections and Community Supervision, he is held in a unit set aside for inmates who because of their high public profile or other factors might be at increased risk of extortion or violence.

The year after entering parliament in 2005, together with other Muslim MPs and peers and Muslim community organisations, he wrote to Blair (then still PM) criticising the Iraq war and UK Middle East policy including attacks on civilians arguing that it put civilians at increased risk in the UK and abroad.

When children are not vaccinated, they are at increased risk and can spread diseases to other in their family and community — including babies who are too young to be vaccinated, and people with weakened immune systems due to cancer and other health conditions.

«But in this case, when this virus infects cells, the virus makes its own transcription factors, and those sit on the human genome at lupus risk variants (and at the variants for other diseases) and that's what we suspect is increasing risk for the disease.»

A far - reaching study conducted by scientists at Cincinnati Children's reports that the Epstein - Barr virus (EBV)-- best known for causing mononucleosis — also increases the risks for some people of developing seven other major diseases.

The medications excel at quelling hallucinations and delusions, yet largely fail to address schizophrenia's debilitating cognitive and social impairments, while increasing risk for movement disorders, weight gain, and other metabolic and cardiovascular side effects.

Researchers at the University of Maryland School of Medicine have identified a mutation in a fat - storage gene that appears to increase the risk for type 2 diabetes and other metabolic disorders, according to a study published online in the New England Journal of Medicine.

Unfortunately for birds and many other organisms, it's crowded at the top: Shifting habitats higher up may increase extinction risks as competition between species increases and viable environments get narrower and eventually run out, said Forero - Medina.

Students who resided with fewer than two parents, who earned over $ 50 per week from sources other than a job, or who go out 4 - 7 nights per week for fun, were at significantly increased risk for use.

After adjustment for other characteristics, current smokers remained at significantly increased risk of reoperation for infectious complications — the relative risk was 80 percent higher, compared to nonsmokers.

«Phenocopy can be caused by other risk - modifying genes or exposure patterns that increase the probability of the specific phenotype manifesting itself,» says the study's first author Hildur Helgadottir, researcher at Karolinska Institutet's Department of Oncology - Pathology, Stockholm, Sweden.

The team is now examining telomere length in additional populations to evaluate whether some groups based on age, gender, smoking history and other factors may be at additional increased risk.

While the Johns Hopkins team studies the likely effects of radiation on the brain during a deep space mission, other NASA - funded research groups are looking at the potential effects of radiation on other parts of the body and on whether it increases cancer risks.

«People with psoriasis, particularly those with more severe disease, have an increased risk for a variety of other health problems, including obesity, diabetes, high blood pressure, high cholesterol, stroke and heart attack,» says board - certified dermatologist Jashin J. Wu, MD, FAAD, director of dermatology research at the Kaiser Permanente Los Angeles Medical Center.

Research at the time indicated the latter increased the virulence of the former when combined with each other, allowing the injections to induce the feverish effects while drastically reducing the risk of death.

Even more troubling, her study found a link between high blood levels of lycopene's chemical cousin, beta - carotene, and an increased risk of aggressive prostate cancer — not enough to justify avoiding carrots and other food sources of beta - carotene but an ominous sign that not all food - derived compounds are necessarily benign when taken at higher doses.

This study has potential clinical significance since children with a history of ROP are not only at increased risk for visual impairments from the ROP itself, but are also at increased risk for developing other ocular disorders later in life.»

Higher levels of autistic traits were also associated with increased vulnerability to experiencing feelings of depression, feeling they are a burden on others, and do not belong in the world, which may put them at more risk of attempting suicide.